PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(01): 100-107
DOI: 10.1055/s-0041-1729725
How I treat

How I Treat Metastatic Hormone-Sensitive Prostate Cancer?

Deepak Dabkara
1   Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Debapriya Mondal
1   Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Joydeep Ghosh
1   Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Bivas Biswas
1   Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Sandip Ganguly
1   Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). When multiple options are available, the dilemma remains how to choose among these options. Similarly, issues of bone health, long-term side effects of therapies, and hereditary risk need to be discussed for comprehensive care. In the present article, we reviewed the relevant evidence for the treatment of mHSPC. ADT alone is not the current standard of care for most patients. In these times of plenty and price crisis, it is imperative to find the best option for treating these patients.

Keywords

hormone-sensitive - metastatic - prostate


Publikationsverlauf

Artikel online veröffentlicht:
28. Mai 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Balasubramaniam G, Talole S, Mahantshetty U, Saoba S, Shrivastava S. Prostate cancer: a hospital-based survival study from Mumbai, India. Asian Pac J Cancer Prev 2013; 14 (04) 2595-2598
    CrossrefPubMedGoogle Scholar
  • 2 Tangen CM, Hussain MH, Higano CS. et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 2012; 188 (04) 1164-1169
    CrossrefPubMedGoogle Scholar
  • 3 Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987; 138 (04) 804-806
    CrossrefPubMedGoogle Scholar
  • 4 Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990; 144 (04) 934-941
    CrossrefPubMedGoogle Scholar
  • 5 Sciarra A, Fasulo A, Ciardi A. et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine (Baltimore) 2016; 95 (27) e3845
    CrossrefPubMedGoogle Scholar
  • 6 Melloni C, Slovin SF, Blemings A. et al. Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design. J Am Coll Cardiol CardioOncol 2020; 2: 70-81
    Google Scholar
  • 7 Shore ND, Saad F, Cookson MS. et al. HERO Study Investigators. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020; 382 (23) 2187-2196
    CrossrefPubMedGoogle Scholar
  • 8 Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013; 111 (04) 543-548
    CrossrefPubMedGoogle Scholar
  • 9 Gaztañaga M, Crook J. Androgen deprivation therapy: minimizing exposure and mitigating side effects. J Natl Compr Canc Netw 2012; 10 (09) 1088-1095, quiz 1088, 1096
    CrossrefPubMedGoogle Scholar
  • 10 Hussain M, Tangen CM, Berry DL. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368 (14) 1314-1325
    CrossrefPubMedGoogle Scholar
  • 11 Klotz L, O’Callaghan CJ, Ding K. et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. JCO 2011; 29 (07) (Suppl. 01) 3
    CrossrefGoogle Scholar
  • 12 Tannock IF, de Wit R, Berry WR. et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15) 1502-1512
    CrossrefPubMedGoogle Scholar
  • 13 Petrylak DP, Tangen CM, Hussain MH. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15) 1513-1520
    CrossrefPubMedGoogle Scholar
  • 14 Sweeney CJ, Chen YH, Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373 (08) 737-746
    CrossrefPubMedGoogle Scholar
  • 15 Gravis G, Fizazi K, Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14 (02) 149-158
    CrossrefPubMedGoogle Scholar
  • 16 Vale CL, Fisher DJ, White IR. et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol 2018; 29 (05) 1249-1257
    CrossrefPubMedGoogle Scholar
  • 17 Kyriakopoulos CE, Chen YH, Carducci MA. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018; 36 (11) 1080-1087
    CrossrefPubMedGoogle Scholar
  • 18 Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial-The Lancet. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736 (15) 01037–5/fulltext. Accessed April 9, 2021
  • 19 Addition of Docetaxel to Hormonal Therapy in Low- and High-Burden Metastatic Hormone Sensitive Prostate Cancer. Long-Term Survival Results from the STAMPEDE Trial | Annals of Oncology | Oxford Academic. Available from: https:// academic.oup.com/annonc/article/30/12/1992/5574397. Accessed April 9, 2021
  • 20 Schweizer MT, Gulati R, Mostaghel EA. et al. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Med Oncol 2016; 33 (07) 77
    CrossrefPubMedGoogle Scholar
  • 21 Ryan CJ, Smith MR, de Bono JS. et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (02) 138-148
    CrossrefPubMedGoogle Scholar
  • 22 de Bono JS, Logothetis CJ, Molina A. et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21) 1995-2005
    CrossrefPubMedGoogle Scholar
  • 23 Abiraterone Plus Prednisone in Metastatic. Castration-Sensitive Prostate Cancer | NEJM. Available from: https://www.nejm.org/doi/ full/10.1056/NEJMoal704174. Accessed April 9, 2021
  • 24 Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy | NEJM. Available from: https://www.nejm. org/doi/full/10.1056/NEJMoal702900. Accessed April 9, 2021
  • 25 Rajput A, Hussain SM, Sonthwal N. et al. Clinicoradiological profile and treatment outcomes in prostate cancer at a tertiary care cancer center in India. Indian J Med Paediatr Oncol 2020; 41: 187-192
    Artikel in Thieme ConnectGoogle Scholar
  • 26 Hoyle AP, Ali A, James ND. et al. STAMPEDE Investigators. Abiraterone in “High-” and “Low-risk” metastatic hormone-sensitive prostate cancer. Eur Urol 2019; 76 (06) 719-728
    CrossrefPubMedGoogle Scholar
  • 27 Adding Abiraterone or Docetaxel to Long-Term Hormone Therapy for Prostate Cancer: Directly Randomised Data from the STAMPEDE Multi-Arm, Multi-Stage Platform Protocol | Annals of Oncology | Oxford Academic. Available from: https:// academic.oup.com/annonc/article/29/5/1235/49105 1 3. Accessed April 9, 2021
  • 28 Hussain M, Fizazi K, Saad F. et al. Enzalutamide in Men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018; 378 (26) 2465-2474
    CrossrefPubMedGoogle Scholar
  • 29 Penson DF, Armstrong AJ, Concepcion R. et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol 2016; 34 (18) 2098-2106
    CrossrefPubMedGoogle Scholar
  • 30 Davis ID, Martin AJ, Stockler MR. et al. ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019; 381 (02) 121-131
    CrossrefPubMedGoogle Scholar
  • 31 Armstrong AJ, Szmulewitz RZ, Petrylak DP. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019; 37 (32) 2974-2986
    CrossrefPubMedGoogle Scholar
  • 32 Chi KN, Agarwal N, Bjartell A. et al. TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019; 381 (01) 13-24
    CrossrefPubMedGoogle Scholar
  • 33 Astellas Pharma US. Inc., Enzalutamide. U.S. Food and Drug Administration; 2019. Available from: https://www.accessdata. fda.gov/drugsatfda_docs/label/2019/203415s0151bl.pdf. Accessed April 9, 2021
  • 34 Janssen Pharmaceutical Companies. Apalutamide. U.S. Food and Drug Administration; 2019. Available from: https://www. accessdata.fda.gov/drugsatfda_docs/label/2019/210951s0011bl.pdf. Accessed April 9, 2021
  • 35 Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352 (02) 154-164
    CrossrefPubMedGoogle Scholar
  • 36 Bubendorf L, Schöpfer A, Wagner U. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31 (05) 578-583
    CrossrefPubMedGoogle Scholar
  • 37 Immediate Dual Energy X-ray Absorptiometry Reveals a High Incidence of Osteoporosis in Patients with Advanced Prostate Cancer before Hormonal Manipulation-Hussain-2003-BJU International-Wiley Online Library. Available from: https:// onlinelibrary.wiley.com/doi/full/10.1046/j. 1464–410X.2003.0447 1. x?sid=nlm%3Apubmed. Accessed April 9, 2021
  • 38 Overview Prostate Cancer. Diagnosis and Management | Guidance | NICE. Available from: https://www. nice.org.uk/guidance/ngl31. Accessed April 9, 2021
  • 39 Mottet N, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71 (04) 618-629
    CrossrefPubMedGoogle Scholar
  • 40 FRAX. Available from. https://www.sheffield.ac.uk/FRAX/. Accessed April 9, 2021
  • 41 James H II, Aleksic I, Bienz MN. et al. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy. Urology 2014; 84 (01) 164-168
    CrossrefPubMedGoogle Scholar
  • 42 Smith MR, Halabi S, Ryan CJ. et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 2014; 32 (11) 1143-1150
    CrossrefPubMedGoogle Scholar
  • 43 Denosumab for the Prevention of Skeletal Complications in Metastatic Castration-Resistant Prostate Cancer. Comparison of Skeletal-Related Events and Symptomatic Skeletal Events. Annals of Oncology. Available from: https://www.annalsofoncology.org/ article/S0923–7534(19)31373–0/fulltext. Accessed April 9, 2021
  • 44 Fizazi K, Carducci M, Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377 (97/68) 813-822
    CrossrefPubMedGoogle Scholar
  • 45 Smith MR, Saad F, Coleman R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379 (98/10) 39-46
    CrossrefPubMedGoogle Scholar
  • 46 Smith MR, Egerdie B, Hernández Toriz N. et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361 (08) 745-755
    CrossrefPubMedGoogle Scholar
  • 47 Home. National Osteoporosis Foundation. Available from: https://www.nof.org/. Accessed April 9, 2021
  • 48 Official Positions ISCD. Available from: https://www.iscd.org/ official-positions/. Accessed April 9, 2021
  • 49 Boevé LMS, Hulshof MCC, Vis AN. et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 2019; 75 (03) 410-418
    CrossrefPubMedGoogle Scholar
  • 50 Parker CC, James ND, Brawley CD. et al. Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392 (10/162) 2353-2366
    CrossrefPubMedGoogle Scholar
  • 51 Burdett S, Boevé LM, Ingleby FC. et al. STOPCAP M1 Radiotherapy Collaborators. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol 2019; 76 (01) 115-124
    CrossrefPubMedGoogle Scholar
  • 52 Trabulsi EJ, Rumble RB, Jadvar H. et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol 2020; 38 (17) 1963-1996
    CrossrefPubMedGoogle Scholar
  • 53 National Comprehensive Cancer Network. Prostate Cancer (Version 2.2020). Available from: https://www.nccn.org/ professionals/physician_gls/pdf/prostate.pdf. Accessed April 9, 2021
  • 54 Cornford P, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 71 (04) 630-642
    CrossrefPubMedGoogle Scholar
  • 55 Gillessen S, Attard G, Beer TM. et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 2018; 73 (02) 178-211
    CrossrefPubMedGoogle Scholar
  • 56 Giri VN, Knudsen KE, Kelly WK. et al. Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019. J Clin Oncol 2020; 38 (24) 2798-2811
    CrossrefPubMedGoogle Scholar
  • 57 de Bono J, Mateo J, Fizazi K. et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020; 382 (22) 2091-2102
    CrossrefPubMedGoogle Scholar
  • 58 Abida W, Patnaik A, Campbell D. et al. TRITON2 investigators. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 BRCA2 gene alteration. J Clin Oncol 2020; 38 (32) 3763-3772
    CrossrefPubMedGoogle Scholar
  • 59 Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer. Urol Oncol 2019; 37 (10) 688-695
    CrossrefPubMedGoogle Scholar
  • 60 Singh P, Agrawal T, Yadav S, Nayak B, Seth A, Dogra PN. A comparative study of the effects of medical versus surgical androgen deprivation therapy on health-related quality of life in patients with metastatic carcinoma prostate. Indian J Cancer 2018; 55 (02) 148-153
    CrossrefPubMedGoogle Scholar
  • 61 Smith MR, Saad F, Hussain M. et al. ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). JCO 2018; 36 (Suppl. 06) TPS383-TPS383
    CrossrefGoogle Scholar
  • 62 Attard G, Sydes MR, Mason MD. et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 2014; 66 (05) 799-802
    CrossrefPubMedGoogle Scholar
  • 63 A Phase III Study for Patients with Metastatic Hormone-Naive Prostate Cancer-Full Text View-ClinicalTrials.Gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01957436. Accessed April 9, 2021